PT1259477E - Derivados de aminoadamantano como agentes terapeuticos - Google Patents

Derivados de aminoadamantano como agentes terapeuticos

Info

Publication number
PT1259477E
PT1259477E PT01916217T PT01916217T PT1259477E PT 1259477 E PT1259477 E PT 1259477E PT 01916217 T PT01916217 T PT 01916217T PT 01916217 T PT01916217 T PT 01916217T PT 1259477 E PT1259477 E PT 1259477E
Authority
PT
Portugal
Prior art keywords
derivatives
disorders
trauma
neurological
methods
Prior art date
Application number
PT01916217T
Other languages
English (en)
Inventor
Wang Yuqiang
Ye Wenqing
James W Larrick
Jonathan S Stamler
Stuart A Lipton
Original Assignee
Panorama Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panorama Res Inc filed Critical Panorama Res Inc
Publication of PT1259477E publication Critical patent/PT1259477E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT01916217T 2000-02-22 2001-02-22 Derivados de aminoadamantano como agentes terapeuticos PT1259477E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/510,099 US6444702B1 (en) 2000-02-22 2000-02-22 Aminoadamantane derivatives as therapeutic agents

Publications (1)

Publication Number Publication Date
PT1259477E true PT1259477E (pt) 2005-08-31

Family

ID=24029379

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01916217T PT1259477E (pt) 2000-02-22 2001-02-22 Derivados de aminoadamantano como agentes terapeuticos

Country Status (14)

Country Link
US (5) US6444702B1 (pt)
EP (2) EP1568685A1 (pt)
JP (1) JP4317343B2 (pt)
CN (1) CN100339356C (pt)
AT (1) ATE294774T1 (pt)
AU (2) AU4327101A (pt)
BR (1) BR0108547A (pt)
CA (1) CA2400916C (pt)
DE (1) DE60110557T2 (pt)
ES (1) ES2243468T3 (pt)
HK (1) HK1052921A1 (pt)
MX (1) MXPA02008170A (pt)
PT (1) PT1259477E (pt)
WO (1) WO2001062706A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
EP1852113A3 (en) * 2000-12-07 2008-03-12 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
MXPA03005130A (es) * 2000-12-07 2004-12-06 Neuromolecular Inc Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda.
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
WO2003068726A1 (fr) * 2001-12-27 2003-08-21 Daicel Chemical Industries, Ltd. Derive amide d'amine alicyclique et procede de production de celui-ci
US20060247216A1 (en) * 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
AU2003286829A1 (en) 2002-11-01 2004-06-07 Bridgestone/Firestone North American Tire, Llc Method for designing tire noise pitch sequence
EP1578413A2 (en) * 2002-11-29 2005-09-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
US20050124701A1 (en) * 2003-06-11 2005-06-09 Went Gregory T. Method of targeting a therapeutic agent
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
CN100363329C (zh) * 2004-01-09 2008-01-23 南京大学 合成美金刚胺盐酸盐的方法
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
MXPA06014587A (es) * 2004-06-17 2007-04-27 Forest Laboratories Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
EP1765287A2 (en) 2004-06-17 2007-03-28 Merz Pharma GmbH & Co. KGaA Immediate release formulations of memantine oral dosage forms
US20080275112A1 (en) * 2004-07-23 2008-11-06 Schreiner Peter R Invention Concerning Aminoadamantane Compounds
EP1827385B1 (en) 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20080009546A1 (en) * 2005-05-06 2008-01-10 Chevron U.S.A. Inc. Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
WO2006122054A1 (en) * 2005-05-06 2006-11-16 Chevron U.S.A. Inc. Diamondoid derivatives possessing therapeutic activity
AU2006259619A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
EP2040676A2 (en) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Orally dissolving formulations of memantine
CN101450911B (zh) * 2007-11-30 2012-02-29 山东轩竹医药科技有限公司 被金刚烷取代的苯甲酸衍生物
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
KR100998525B1 (ko) * 2008-03-28 2010-12-07 나노다이아몬드 주식회사 아밀로이드 올리고머 독성 억제제로서의 아다만탄 유도체
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
CN103833555B (zh) * 2012-11-23 2016-12-21 上海京新生物医药有限公司 一种盐酸美金刚的制备方法
WO2014117089A1 (en) 2013-01-25 2014-07-31 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN105294450B (zh) * 2014-05-29 2024-05-17 广州喜鹊医药有限公司 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
US10800734B2 (en) * 2016-05-07 2020-10-13 Sunshine Lake Pharma Co., Ltd. Memantine compounds and their preparation and uses thereof
US10214478B2 (en) * 2016-11-28 2019-02-26 Guangzhou Magpie Pharmaceuticals Co., Ltd. Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof
WO2019028025A1 (en) 2017-08-01 2019-02-07 Lipton Stuart A METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS
US11447442B2 (en) 2017-11-22 2022-09-20 Panorama Research, Inc. Aminoadamantyl nitrate compounds and their use to treat CNS disorders
CN111662216A (zh) * 2019-03-05 2020-09-15 广东东阳光药业有限公司 一种金刚烷胺类化合物的晶型及其制备方法
CN110938006A (zh) * 2019-12-04 2020-03-31 重庆植恩药业有限公司 盐酸美金刚杂质c的制备方法
WO2021231582A1 (en) * 2020-05-12 2021-11-18 Eumentis Therapeutics, Inc. Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia
CN117427057A (zh) * 2022-07-14 2024-01-23 广州喜鹊医药有限公司 金刚烷硝酸酯类化合物在制备预防或治疗细胞因子风暴药物中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
GB1173492A (en) 1966-02-18 1969-12-10 Upjohn Co Acylamino-Adamantane Derivatives
CH603545A5 (pt) 1972-04-20 1978-08-31 Merz & Co
US4351847A (en) 1981-06-26 1982-09-28 Pennwalt Corporation Antiviral alpha, alpha-dialkyl adamantylethylamines
US4346112A (en) 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS584718A (ja) 1981-06-30 1983-01-11 Nippon Chibagaigii Kk 新規適応症に用うる医薬製剤
EP0465565B1 (en) 1989-03-31 1996-05-15 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
EP0486621A4 (en) 1989-08-09 1993-03-31 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
US5091391A (en) 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6071876A (en) 1991-04-19 2000-06-06 Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
WO1992018112A1 (en) 1991-04-19 1992-10-29 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
JPH06161125A (ja) 1992-11-17 1994-06-07 Mita Ind Co Ltd 電子写真感光体
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5677349A (en) * 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
DE19531342B4 (de) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5776935A (en) 1996-07-25 1998-07-07 Merz & Co. Gmbh & Co. Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission
US6468487B1 (en) * 1997-01-14 2002-10-22 Daicel Chemical Industries, Ltd. Nitration or carboxylation catalysts
US6392104B1 (en) * 1997-03-11 2002-05-21 Daicel Chemical Industries, Ltd. Adamantane derivatives and process for producing them
PT870757E (pt) 1997-04-10 2002-09-30 Pfizer Derivados de adamantano substituidos por fluoro
US6071966A (en) 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
CZ293248B6 (cs) 1997-06-30 2004-03-17 Merz Pharma Gmbh & Co. Kgaa 1-Aminocyklohexanový derivát a farmaceutická kompozice na jeho bázi
MA26553A1 (fr) 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
GB9726388D0 (en) 1997-12-12 1998-02-11 Cerebrus Ltd Chemical compounds
WO1999037149A1 (en) 1998-01-27 1999-07-29 Brigham & Women's Hospital Methods of treating cytotoxic damage
JP4626896B2 (ja) * 1998-02-13 2011-02-09 ダイセル化学工業株式会社 アシル化剤とそれを用いたアシル化法、及びアダマンタン誘導体
JP4222493B2 (ja) * 1998-04-21 2009-02-12 ダイセル化学工業株式会社 アダマンタンメタノール誘導体及びその製造法
JP4215858B2 (ja) 1998-04-21 2009-01-28 ダイセル化学工業株式会社 アダマンタノール誘導体及びその製造法
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
US20040009613A1 (en) 2001-02-16 2004-01-15 Ming-Ming Zhou Methods of identifying modulators of bromodomains
US7589167B2 (en) 2000-02-22 2009-09-15 J. David Gladstone Institutes ZA loops of bromodomains
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US6602862B1 (en) 2000-09-19 2003-08-05 Merz Pharma Gmbh & Co., Kgaa 1-Amino-alkylcyclohexanes as trypanocidal agents
MXPA03005130A (es) 2000-12-07 2004-12-06 Neuromolecular Inc Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda.
US20040122090A1 (en) 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
WO2002078615A2 (en) 2001-04-02 2002-10-10 Panorama Research, Inc. Antioxidant nitroxides and nitrones as therapeutic agents
JP2003137842A (ja) 2001-10-29 2003-05-14 Tosoh Corp α−フルオロアルキル−２−アダマンチルアクリレート類及びその製造方法
JP2003137841A (ja) 2001-10-29 2003-05-14 Tosoh Corp α−フルオロアルキル−１−アダマンチルアクリレート類及びその製造方法

Also Published As

Publication number Publication date
EP1568685A1 (en) 2005-08-31
DE60110557T2 (de) 2006-04-27
WO2001062706A1 (en) 2001-08-30
AU2001243271B2 (en) 2004-12-09
JP4317343B2 (ja) 2009-08-19
HK1052921A1 (en) 2003-10-03
CA2400916A1 (en) 2001-08-30
US6444702B1 (en) 2002-09-03
ATE294774T1 (de) 2005-05-15
US20030008889A1 (en) 2003-01-09
US20080183003A1 (en) 2008-07-31
MXPA02008170A (es) 2005-07-01
CA2400916C (en) 2012-07-10
AU4327101A (en) 2001-09-03
DE60110557D1 (de) 2005-06-09
BR0108547A (pt) 2003-06-10
JP2003523989A (ja) 2003-08-12
EP1259477B1 (en) 2005-05-04
ES2243468T3 (es) 2005-12-01
US20060106222A1 (en) 2006-05-18
CN100339356C (zh) 2007-09-26
US6620845B2 (en) 2003-09-16
EP1259477A1 (en) 2002-11-27
US20040029929A1 (en) 2004-02-12
US7326730B2 (en) 2008-02-05
CN1446193A (zh) 2003-10-01

Similar Documents

Publication Publication Date Title
PT1259477E (pt) Derivados de aminoadamantano como agentes terapeuticos
HK1008980A1 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders
HUP9904525A2 (hu) S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények
TW200635589A (en) Therapeutic agents
TW200745135A (en) Therapeutic agents
ATE469132T1 (de) Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
ZA972496B (en) Substituted 2,3-benzodiazepin-4-ones and the use thereof.
HK1036792A1 (en) Fluorine-containing amino acid derivatives.
HUP9802862A2 (hu) (1S,2S)-1-(4-hydroxi-fenil)-2-(4-hidroxi-4-fenil-1-piperidinil)-1-propanol-metánszulfonát-trihidrát, és ezt a vegyületet tartalmazó a központi idegrendszeri rendellenességek kezelésére alkalmas gyógyászati készítmények
NO961435D0 (no) Terapeutiske midler
WO2007106862A3 (en) The use of statins to stimulate neurogenesis
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
RU2003102437A (ru) 7-гидроксиэпиандростерон, обладающий нейропротективной активностью
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
WO2005095361A8 (en) Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
DE60004835D1 (de) 7-oxo-2-azabicyclo[2.2.1]heptane als selektive muskarin-rezeptor antagonisten
MXPA01009384A (es) Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina.
DE60209192D1 (de) Inhibitore der Verzweigte-Aminosäure-abhängigen Aminotransferase und deren Verwendung in der Behandlung von Neurodegenerativen Erkrankungen
WO2023107630A3 (en) Amino alcohol compounds and uses thereof
CA2257234A1 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
MX9709911A (es) Compuestos activos en un sitio novedoso en canales de calcio operados por receptor utiles para el tratamiento de trastornos neurologicos.
TW200607809A (en) 4-cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists